Dermatitis : contact, atopic, occupational, drug最新文献

{"title":"Impact of Anxiety on Patch Testing Results for Allergic Contact Dermatitis.","authors":"Jared Boetes, Sarah Kamsiah Zemlok, Kyle Polen, Mykayla Sandler, JiaDe Yu","doi":"10.1177/17103568251364893","DOIUrl":"https://doi.org/10.1177/17103568251364893","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> While patch testing remains the gold standard for diagnosis of allergic contact dermatitis (ACD), the reliability and reproducibility of patch testing results have been questioned in the literature. Various exogenous and endogenous factors have been explored as sources of discordance, but the effect of anxiety on patch testing results has not yet been studied. Anxiety is known to be associated with systemic inflammation and has been shown to increase the incidence of positive reactions in skin prick testing. <u><b><i>Objective:</i></b></u> This study aimed to investigate the impact of anxiety on patch testing results in patients with suspected ACD. <u><b><i>Methods:</i></b></u> Adult subjects (<i>n</i> = 35) presenting to an outpatient patch testing dermatology clinic completed 2 questionnaires on the day of patch placement: the State-Trait Anxiety Inventory (STAI-S) and the Generalized Anxiety Disorder-7 (GAD-7). All participants completed patch testing with the North American Contact Dermatitis Group 80 series. Patches were removed after 48 hours, and a final reading was performed after 120 hours. <u><b><i>Results:</i></b></u> No meaningful correlations were found between the incidence of all positive reactions (±, +, ++, and +++) and participants' STAI-S scores (Pearson's r = -0.036) or GAD-7 scores (Pearson's r = 0.1). Weak negative correlations were identified between the incidence of strong positive reactions (++ and +++) and participants' STAI-S scores (Pearson's r = -0.2) and GAD-7 scores (Pearson's r = -0.2). <u><b><i>Conclusions:</i></b></u> The results of this study suggest that anxiety does not have an impact on patch testing results for patients with suspected ACD. Future studies would benefit from having a larger sample size and greater gender and racial diversity within the study population.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study.","authors":"Gianluca Avallone, Luca Valtellini, Gianluca Tavoletti, Luca Mastorino, Martina Maurelli, Eugenia Veronica Di Brizzi, Elena Ippoliti, Francesca Barei, Davide Termini, Pietro Quaglino, Michela Ortoncelli, Giampiero Girolomoni, Anna Balato, Niccolò Gori, Ketty Peris, Angelo Valerio Marzano, Silvia Mariel Ferrucci, Simone Ribero","doi":"10.1177/17103568251363249","DOIUrl":"10.1177/17103568251363249","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Atopic dermatitis (AD) affecting the head and neck (H&N) area poses a clinical challenge due to the unique anatomical and physiological features of this region. Despite its well-documented impact on quality of life (QoL), evidence on the effectiveness of tralokinumab in treating AD specifically in the H&N area remains limited. <u><b><i>Objective:</i></b></u> To assess the clinical outcomes of tralokinumab in AD patients with H&N involvement, informing clinical decision-making and improving patient care. <u><b><i>Methods:</i></b></u> A multicenter, retrospective cohort study across 5 Italian tertiary referral hospitals. Patients were stratified by H&N involvement, and treatment outcomes were assessed using the Eczema Area and Severity Index (EASI), EASI H&N, Investigator Global Assessment (IGA), Numerical Rating Scale (NRS) pruritus, NRS sleep, Dermatology Life Quality Index, Patient-Oriented Eczema Measure, and Atopic Dermatitis Control Tool. <u><b><i>Results:</i></b></u> Among 211 patients, 145 (68.7%) had H&N involvement. A significant reduction in EASI H&N scores from baseline to weeks 12-16 (38.1%) and week 24 (54.5%) was achieved. Significant improvements in IGA, NRS pruritus, and NRS sleep, and QoL measures emerged within 12-16 weeks and persisted at 24 weeks. Compared with patients without H&N involvement, those with H&N involvement exhibited a stronger atopic background and showed no evidence of reduced drug survival. Adverse events, mainly conjunctivitis, were comparable between groups. <u><b><i>Conclusions:</i></b></u> Tralokinumab is effective and well-tolerated in managing moderate-to-severe AD involving the H&N area, even in biologic-experienced patients. These findings support its use as a targeted therapy addressing both clinical and psychosocial burdens of H&N AD.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dental Amalgam-Induced Pigmentous Lichen Planus: A Manifestation of Mercury Hypersensitivity.","authors":"Nesrine Ben Salah, Amal Hamdi, Mouna Korbi, Monia Youssef, Samiha Mabrouk, Hichem Belhadjali, Jameleddine Zili","doi":"10.1177/17103568251364235","DOIUrl":"https://doi.org/10.1177/17103568251364235","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> When Hair Straightening Turns Harmful: Acute Toxic Contact Dermatitis Induced by Straight Hair Treatment.","authors":"Sirine Bchir, Mouna Hamouda, Nesrine Ben Salah, Mouna Korbi, Aicha Aly, Asma Ben Mabrouk, Jameleddine Zili, Habib Skhiri","doi":"10.1177/17103568251364236","DOIUrl":"https://doi.org/10.1177/17103568251364236","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thirty-Six-Week Real-World Effectiveness of Lebrikizumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: Results from a Prospective Japanese Study.","authors":"Teppei Hagino, Akihiko Uchiyama, Keiji Kosaka, Takeshi Araki, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda","doi":"10.1177/17103568251361920","DOIUrl":"https://doi.org/10.1177/17103568251361920","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Anti-interleukin-13 antibody lebrikizumab is highly effective and tolerable for atopic dermatitis (AD). However, real-world data are limited on its effectiveness for different anatomical sites and clinical signs. <u><b><i>Objective:</i></b></u> To evaluate the effectiveness of lebrikizumab on different anatomical sites and clinical signs of AD. <u><b><i>Methods:</i></b></u> This study included 162 patients with moderate-to-severe AD who received lebrikizumab for 36 weeks. Eczema Area and Severity Index (EASI) was assessed at weeks 0, 4, 12, 24, and 36 on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs) and four clinical signs (erythema, edema/papulation, excoriation, and lichenification). <u><b><i>Results:</i></b></u> Lebrikizumab consistently decreased EASI on all anatomical sites and all clinical signs through 36 weeks. Week 36 achievement rates of EASI 100 on the trunk and upper limbs (46.3% and 48.8%) were higher compared to head/neck and lower limbs (28.9% and 33.3%), respectively. The percentage reduction of EASI and achievement rates of EASI 75 and EASI 100 at each time-point were highest for excoriation among clinical signs; week 36 achievement rates of EASI 100 for erythema, edema/papulation, excoriation, and lichenification were 35.3%, 38.2%, 60.6%, and 37.1%, respectively. <u><b><i>Conclusions:</i></b></u> Lebrikizumab consistently improves eruptions across all anatomical sites and clinical signs in AD throughout 36 weeks.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional, and National Burden of Dermatitis from 1990 to 2021, and Forecasts to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021.","authors":"Songtao Tan, Haojing Tang, Guiying Li, Jiaqi Zhao, Xin Xin, Suyao Wang, Di Wu","doi":"10.1089/derm.2024.0545","DOIUrl":"https://doi.org/10.1089/derm.2024.0545","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Dermatitis significantly impacts global health, affecting both physical discomfort and mental health. However, its full scope remains under-appreciated, necessitating further analysis to inform effective public health strategies. <u><b><i>Objective:</i></b></u> This research aims to provide an updated assessment of the global, regional, and national burden of dermatitis using data from Global Burden of Disease 2021 database. <u><b><i>Methods:</i></b></u> We analyzed incidence cases, age-standardized incidence rates (ASIR), disability-adjusted life years (DALYs), and age-standardized DALYs rates (ASDR) by region, sex, age, and disease type. Temporal trends were examined using percentage change and estimated annual percentage change. <u><b><i>Results:</i></b></u> In 2021, dermatitis caused 405 million incidence cases and 8.2 million DALYs, reflecting a 63% and 32% increase from 1990, respectively. ASIR and ASDR were stable overall but varied significantly by demographic factors. Females exhibited higher ASIR and ASDR than males. A negative correlation was found between socio-demographic index (SDI) and ASIR (r = -0.62, <i>P</i> < 0.001), while ASDR correlated positively with SDI (r = 0.69, <i>P</i> < 0.001). <u><b><i>Conclusions:</i></b></u> Dermatitis burden continues to rise, driven primarily by population growth. Significant disparities persist across regions, ages, and sexes and targeted interventions are urgently needed.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy.","authors":"Teppei Hagino, Akihiko Uchiyama, Keiji Kosaka, Takeshi Araki, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda","doi":"10.1177/17103568251361929","DOIUrl":"https://doi.org/10.1177/17103568251361929","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> The transition of blood biomarkers has not been precisely examined in real-world treatments with anti-interleukin (IL)-13 antibodies for atopic dermatitis (AD). <u><b><i>Objective:</i></b></u> To evaluate the transition of blood biomarkers during 24-week treatment with lebrikizumab or tralokinumab for patients with AD in real-world settings, stratified by the presence or absence of prior systemic therapy. <u><b><i>Methods:</i></b></u> We conducted a retrospective study of Japanese patients with AD who received lebrikizumab (<i>n</i> = 148) or tralokinumab (<i>n</i> = 173). We measured serum immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) at weeks 0, 4, 12, and 24 in systemic therapy-naïve or -experienced patients. <u><b><i>Results:</i></b></u> IgE, TARC, and LDH decreased throughout the 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy-naïve and -experienced patients, and the magnitudes of decreasing IgE and TARC or increasing TEC were higher in the latter. <u><b><i>Conclusion:</i></b></u> IgE, TARC, and LDH decreased during 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy- naïve and -experienced patients.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis.","authors":"Yan Zhao, Cheng Zhou, Xiaoyong Man, Bing Liu, Songmei Geng, Yunsheng Liang, Ying Li, Siping Zhang, Shuxia Yang, Huichun Su, Hengguang Zhao, Xiang Nong, Ying Gao, Wenzhong Wu, Chunxing Xu, Liangchun Wang, Qi Wang, Lunfei Liu, Xiaohong Zhu, Qiuhe Song, Juan Su, Lixia Zhang, Jianyun Lu, Guohong Hu, Hongyi Li, Yuanyuan Shang, Fulun Li, Yifei Wang, Lixiong Gu, Hui Chen, Huiping Wang, Ningning Dang, Fang Cheng, Bo Chen, Yanping Qiu, Chao Liang, Jianzhong Zhang","doi":"10.1177/17103568251361896","DOIUrl":"https://doi.org/10.1177/17103568251361896","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Stapokibart is a novel anti-interleukin-4 receptor α subunit monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD) in adults. <u><b><i>Objective:</i></b></u> To evaluate the feasibility of extending dosing interval of stapokibart based on efficacy response in AD. <u><b><i>Methods:</i></b></u> In this ongoing, multicenter, open-label, single-arm trial (NCT06116565), stapokibart 300 mg was administered subcutaneously every 2 weeks (Q2W) for 12 weeks, followed by dosing interval adjustments at weeks 12 and 36. At week 12, nonresponders (failed to achieve ≥50% improvement from baseline in Eczema Area and Severity Index [EASI-50]) were withdrawn, fast responders (achieved ≥75% improvement from baseline in EASI score [EASI-75] or Investigator's Global Assessment score of 0/1 [IGA 0/1]) were extended to every 4 weeks (Q4W), and slow responders (achieved EASI-50 but not EASI-75 or IGA 0/1) continued Q2W dosing. At week 36, fast responders achieving ≥90% improvement from baseline in EASI score (EASI-90) or IGA 0/1 were further extended to every 8 weeks (Q8W) (Q2W-Q4W-Q8W group), slow responders with EASI-90 or IGA 0/1 were extended to Q4W (Q2W-Q2W-Q4W group), and others maintained their prior dosing through week 52 (Q2W-Q4W-Q4W and Q2W-Q2W-Q2W groups). <u><b><i>Results:</i></b></u> As of April 7, 2025, 256 and 200 patients completed 12 and 36 weeks of treatment, respectively. In the Q2W-Q4W-Q8W group, 93.0%, 73.7%, and 70.7% of patients sustained EASI-75, IGA 0/1, and ≥4-point reduction in weekly average of daily Peak Pruritus Numerical Rating Scale at week 52, versus 99.2%, 90.1%, and 71.1% at week 36, and 98.3%, 54.5%, and 58.3% at week 12. These response rates in the Q2W-Q4W-Q4W group were 96.2%, 23.1%, and 38.5% at week 12, versus 81.8%, 63.6%, and 72.7% at week 52. In the Q2W-Q2W-Q4W group, these responses were achieved in 95.8%, 83.3%, and 77.3% of patients at week 36, increasing to 100%, 80.0%, and 80.0% at week 52. In the Q2W-Q2W-Q2W group, 84.6%, 23.1%, and 71.4% of patients progressively achieved these responses at week 52 with continued standard dosing. The overall incidence of treatment-emergent adverse events was 78.6%, mostly mild or moderate. <u><b><i>Conclusion:</i></b></u> Extending dosing interval of stapokibart based on efficacy response demonstrated sustained efficacy and favorable safety in AD.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Differentiating Between Atopic Dermatitis and Non-Atopic Eczema Using Metabolomics.","authors":"Yan Zheng, Yueyuan Wang, Gen Yang, Guangwen Yin","doi":"10.1177/17103568251360263","DOIUrl":"https://doi.org/10.1177/17103568251360263","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Consider a Low-Metal Diet in Metal-Allergic Dyshidrotic Eczema Patients Prior to Advanced Systemic Therapy.","authors":"Scott J Mahlberg, Kelly B Scarberry, Susan T Nedorost","doi":"10.1089/derm.2025.0055","DOIUrl":"https://doi.org/10.1089/derm.2025.0055","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}